Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Common Equity: 2009-2024

Historic Common Equity for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $830.4 million.

  • Ligand Pharmaceuticals' Common Equity rose 12.96% to $950.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $950.2 million, marking a year-over-year increase of 12.96%. This contributed to the annual value of $830.4 million for FY2024, which is 18.48% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Common Equity stood at $830.4 million for FY2024, which was up 18.48% from $700.9 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Common Equity ranged from a high of $830.4 million in FY2024 and a low of $597.5 million during FY2022.
  • Its 3-year average for Common Equity is $709.6 million, with a median of $700.9 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first dropped by 27.24% in 2022, then increased by 18.48% in 2024.
  • Ligand Pharmaceuticals' Common Equity (Yearly) stood at $709.5 million in 2020, then increased by 15.73% to $821.2 million in 2021, then decreased by 27.24% to $597.5 million in 2022, then increased by 17.31% to $700.9 million in 2023, then climbed by 18.48% to $830.4 million in 2024.